‌

US Patent 11634422 Inhibitors of activin receptor-like kinase

Patent 11634422 was granted and assigned to Blueprint Medicines on April, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Blueprint Medicines

0

Current Assignee

Blueprint Medicines

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brett D. Williams0

Paul E. Fleming0

Natasja Brooijmans0

Mark Cronin0

Kevin J. Wilson0

Joseph L. Kim0

Jason D. Brubaker0

Douglas Wilson0

...

Date of Patent

April 25, 2023

0

Patent Application Number

168872620

Date Filed

May 29, 2020

0

Patent Citations

US Patent 10196436 Inhibitors of the fibroblast growth factor receptor

0

US Patent 10233186 Inhibitors of activin receptor-like kinase

0

US Patent 10807985 Compositions useful for treating disorders related to kit

0

US Patent 10669277 Inhibitors of activin receptor-like kinase

0

US Patent 10000490 Inhibitors of the fibroblast growth factor receptor

0

US Patent 10000496 Compositions useful for treating disorders related to kit and PDGFR

0

US Patent 10017512 Compounds and compositions useful for treating disorders related to NTRK

0

US Patent 10030005 Inhibitors of RET

0

...

Patent Primary Examiner

Noble E Jarrell

0

CPC Code

0

0

0

0

0

Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11634422 Inhibitors of activin receptor-like kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.